Supplementary Table 23 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors Federica Pecci , Seshiru Nakazawa , Biagio Ricciuti , Guilherme Harada , Jessica K. Lee , Joao V. Alessi , Adriana Barrichello , Victor R. Vaz , Giuseppe Lamberti , Alessandro Di Federico , Malini M. Gandhi , Dimitris Gazgalis , William W. Feng , Jie Jiang , Simon Baldacci , Marie-Anaïs Locquet , Felix H. Gottlieb , Monica F. Chen , Elinton Lee , Danielle Haradon , Anna Smokovich , Emma Voligny , Tom Nguyen , Vikas K. Goel , Zachary Zimmerman , Sumandeep Atwal , Xinan Wang , Magda Bahcall , Rebecca S. Heist , Sumaiya Iqbal , Nishant Gandhi , Andrew Elliott , Ari M. Vanderwalde , Patrick C. Ma , Balazs Halmos , Stephen V. Liu , Jianwei Che , Alexa B. Schrock , Alexander Drilon , Pasi A. Jänne , Mark M. Awad crossref（2024）
摘要
Oncogenic / likely oncogenic MET TKD mutations in RCC compared to those detected in NSCLC in cohort #2.
更多 查看译文
AI 理解论文
溯源树
样例
